Suchergebnisse - "Weinreich, David M"

PubPharm (6)

1

Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles

enthalten in: Scientific reports | 2023

von Li, D. | Xu, M. | Hooper, A. | +9

2

Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period : a randomised, double-blind, placebo-controlled trial

enthalten in: The Lancet. Infectious diseases | 2022

von Herman, G. | O'Brien, M. | Forleo-Neto, E. | +127

CommentIn: Lancet Infect Dis. 2022 Oct;22(10):1400-1401. - PMID 35803288

3

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

enthalten in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2022

von Isa, F. | Forleo-Neto, E. | Meyer, J. | +28

4

Compassionate Use of REGEN-COV® in Patients With Coronavirus Disease 2019 (COVID-19) and Immunodeficiency-Associated Antibody Disorders

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2022

von Stein, D. | Oviedo-Orta, E. | Kampman, W. | +8

5

Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection : A Phase 2 Dose-Ranging Randomized Clinical Trial

enthalten in: JAMA network open | 2022

von Portal-Celhay, C. | Forleo-Neto, E. | Eagan, W. | +127

6

Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection : A Randomized Clinical Trial

enthalten in: JAMA | 2022

von O'Brien, M. | Forleo-Neto, E. | Sarkar, N. | +136

UpdateOf: medRxiv. 2021 Sep 18;:. - PMID 34159343

1
[1]